Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Completed double-blind portion of the IM101064 study.
Rheumatoid arthritis (RA) for greater than 1 year from the time of initial diagnosis
American College of Rheumatology (ACR) functional class I, II, III
Subjects currently or previously received an anti-TNF therapy at an approved labeled dose for at least 3 months
You may not be if
Subjects with active vasculitis of a major organ system (except subcutaneous rheumatoid nodules)
History of cancer within the last 5 years (other than non-melanoma skin cell cancers cured by local resection)
Clareo Health | Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy
